Fine-tuning of frontline tyrosine kinase inhibitor (tki) therapy in chronic-phase chronic myeloid leukemia: The choice of the right tki for the right patient

Abstract

In an era when tyrosine kinase inhibitors are gaining acceptance in the treatment scene of chronic-phase chronic myeloid leukemia, this editorial focuses on the search for the optimal patient-based frontline treatment option while evaluating a recent study by Tiribelli and colleagues, which is published in this issue of Cancer.